HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CHST14
carbohydrate sulfotransferase 14
Chromosome 15 Β· 15q15.1
NCBI Gene: 113189Ensembl: ENSG00000169105.8HGNC: HGNC:24464UniProt: Q8NCH0
41PubMed Papers
21Diseases
0Drugs
37Pathogenic Variants
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
dermatan sulfate proteoglycan biosynthetic processdermatan sulfate proteoglycan metabolic processprotein bindingextracellular exosomeEhlers-Danlos syndrome, musculocontractural typeAbnormality of the cardiovascular systemEhlers-Danlos syndromegastric cancer
✦AI Summary

CHST14 encodes carbohydrate sulfotransferase 14/dermatan 4-O-sulfotransferase-1 (D4ST1), which catalyzes the transfer of sulfate to the C-4 hydroxyl of N-acetylgalactosamine residues in dermatan sulfate biosynthesis 1. The enzyme plays a critical role in forming 4-O-sulfated iduronic acid blocks in dermatan sulfate, preferentially modifying GalNAc residues in -IdoUA-GalNAc-IdoUA- sequences compared to -GlcUA-GalNAc-GlcUA- sequences 1. CHST14 is essential for proper collagen fibril assembly through dermatan sulfate-proteoglycan interactions, particularly involving decorin 2. Loss-of-function mutations in CHST14 cause musculocontractural Ehlers-Danlos syndrome (mcEDS-CHST14), a severe connective tissue disorder characterized by multiple congenital malformations, progressive skeletal deformities, skin hyperextensibility, and life-threatening complications including large subcutaneous hematomas 3. The deficiency results in negligible dermatan sulfate production and excessive chondroitin sulfate, leading to dispersed collagen fibrils and multisystem fragility 2. Studies using patient-derived iPSCs demonstrate impaired osteogenesis, providing insights into skeletal manifestations 4. CHST14 knockout mice exhibit perinatal lethality with placental vascular abnormalities, highlighting the enzyme's critical role in development 5.

Sources cited
1
CHST14 encodes D4ST1 enzyme and its role in dermatan sulfate biosynthesis and mcEDS pathology
PMID: 26646600
2
Enzyme mechanism, substrate specificity, and pathophysiology of mcEDS including collagen fibril defects
PMID: 31905796
3
Clinical manifestations and complications of mcEDS-CHST14 in large patient cohort
PMID: 34815299
4
iPSC studies showing impaired osteogenesis in mcEDS-CHST14
PMID: 36981001
5
Knockout mouse model showing perinatal lethality and placental vascular abnormalities
PMID: 29206923
Disease Associationsβ“˜21
Ehlers-Danlos syndrome, musculocontractural typeOpen Targets
0.84Strong
Abnormality of the cardiovascular systemOpen Targets
0.45Moderate
Ehlers-Danlos syndromeOpen Targets
0.42Moderate
gastric cancerOpen Targets
0.08Suggestive
major depressive disorderOpen Targets
0.06Suggestive
type 2 diabetes mellitusOpen Targets
0.05Suggestive
pyknoachondrogenesisOpen Targets
0.04Suggestive
breast carcinomaOpen Targets
0.04Suggestive
Alzheimer diseaseOpen Targets
0.03Suggestive
myopathyOpen Targets
0.01Suggestive
astrocytomaOpen Targets
0.01Suggestive
endometrial cancerOpen Targets
0.01Suggestive
Marden-Walker syndromeOpen Targets
0.01Suggestive
glioblastoma multiformeOpen Targets
0.01Suggestive
neoplasmOpen Targets
0.01Suggestive
primitive neuroectodermal tumorOpen Targets
0.01Suggestive
periodontitisOpen Targets
0.01Suggestive
posterior cortical atrophyOpen Targets
0.01Suggestive
cancerOpen Targets
0.00Suggestive
Dravet syndromeOpen Targets
0.00Suggestive
Ehlers-Danlos syndrome, musculocontractural type 1UniProt
Pathogenic Variants37
NM_130468.4(CHST14):c.527_530delinsGACAG (p.Val176fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 176
NM_130468.4(CHST14):c.156_166del (p.Ser53fs)Pathogenic
not provided|Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜…β˜†β˜†2025β†’ Residue 53
NM_130468.4(CHST14):c.878A>G (p.Tyr293Cys)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type|not provided|Ehlers-Danlos syndrome, musculocontractural type 1|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 293
NM_130468.4(CHST14):c.171del (p.Leu58fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 58
NM_130468.4(CHST14):c.610C>T (p.Gln204Ter)Pathogenic
Cardiovascular phenotype|Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜…β˜†β˜†2025β†’ Residue 204
NM_130468.4(CHST14):c.784G>A (p.Glu262Lys)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type|not provided|Ehlers-Danlos syndrome, musculocontractural type 1|CHST14-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 262
NM_130468.4(CHST14):c.755_851del (p.Ser252fs)Pathogenic
not provided|Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜…β˜†β˜†2023β†’ Residue 252
NM_130468.4(CHST14):c.958C>T (p.Arg320Ter)Likely pathogenic
not provided|Ehlers-Danlos syndrome, musculocontractural type|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2023β†’ Residue 320
NM_130468.4(CHST14):c.494del (p.Val165fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2026β†’ Residue 165
NM_130468.4(CHST14):c.597dup (p.Arg200fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2025β†’ Residue 200
NM_130468.4(CHST14):c.783del (p.Glu262fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2025β†’ Residue 262
NM_130468.4(CHST14):c.730del (p.Arg244fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2025β†’ Residue 244
NM_130468.4(CHST14):c.181G>T (p.Glu61Ter)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2025β†’ Residue 61
NM_130468.4(CHST14):c.201_202del (p.Glu67fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2024β†’ Residue 67
NM_130468.4(CHST14):c.638G>C (p.Arg213Pro)Likely pathogenic
Ehlers-Danlos syndrome, musculocontractural type|Ehlers-Danlos syndrome, musculocontractural type 1
β˜…β˜†β˜†β˜†2024β†’ Residue 213
NM_130468.4(CHST14):c.85_95dup (p.Leu34fs)Likely pathogenic
Ehlers-Danlos syndrome, musculocontractural type 1
β˜…β˜†β˜†β˜†2024β†’ Residue 34
NM_130468.4(CHST14):c.626T>C (p.Phe209Ser)Likely pathogenic
Ehlers-Danlos syndrome, musculocontractural type 1
β˜…β˜†β˜†β˜†2024β†’ Residue 209
NM_130468.4(CHST14):c.53_57del (p.Leu18fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2024β†’ Residue 18
NM_130468.4(CHST14):c.88del (p.Ala30fs)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type
β˜…β˜†β˜†β˜†2024β†’ Residue 30
NM_130468.4(CHST14):c.922C>T (p.Gln308Ter)Pathogenic
Ehlers-Danlos syndrome, musculocontractural type 1
β˜…β˜†β˜†β˜†2023β†’ Residue 308
View on ClinVar β†—
Related Genes
PLOD1Protein interaction83%PLOD3Protein interaction83%ZNF469Protein interaction83%CHST15Protein interaction74%DSEProtein interaction73%B4GALT7Protein interaction73%
Tissue Expression6 tissues
Ovary
100%
Heart
74%
Lung
66%
Liver
42%
Brain
22%
Bone Marrow
17%
Gene Interaction Network
Click a node to explore
CHST14PLOD1PLOD3ZNF469CHST15DSEB4GALT7
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q8NCH0
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.92LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.58 [0.37–0.92]
RankingsWhere CHST14 stands among ~20K protein-coding genes
  • #9,982of 20,598
    Most Researched41
  • #1,626of 5,498
    Most Pathogenic Variants37
  • #8,398of 17,882
    Most Constrained (LOEUF)0.92
Genes detectedCHST14
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort.
PMID: 34602496
J Neuromuscul Dis Β· 2022
1.00
2
Vascular abnormalities in the placenta of Chst14-/- fetuses: implications in the pathophysiology of perinatal lethality of the murine model and vascular lesions in human CHST14/D4ST1 deficiency.
PMID: 29206923
Glycobiology Β· 2018
0.90
3
CHST14/D4ST1 deficiency: New form of Ehlers-Danlos syndrome.
PMID: 26646600
Pediatr Int Β· 2016
0.80
4
Recent Advances in the Pathophysiology of Musculocontractural Ehlers-Danlos Syndrome.
PMID: 31905796
Genes (Basel) Β· 2019
0.70
5
Pathophysiological Investigation of Skeletal Deformities of Musculocontractural Ehlers-Danlos Syndrome Using Induced Pluripotent Stem Cells.
PMID: 36981001
Genes (Basel) Β· 2023
0.60